176 related articles for article (PubMed ID: 27859446)
1. Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.
Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Ye RD; Quinn MT
Drug Dev Res; 2017 Feb; 78(1):49-62. PubMed ID: 27859446
[TBL] [Abstract][Full Text] [Related]
2. 2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.
Vergelli C; Schepetkin IA; Ciciani G; Cilibrizzi A; Crocetti L; Giovannoni MP; Guerrini G; Iacovone A; Kirpotina LN; Khlebnikov AI; Ye RD; Quinn MT
Bioorg Med Chem; 2016 Jun; 24(11):2530-2543. PubMed ID: 27134116
[TBL] [Abstract][Full Text] [Related]
3. Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.
Crocetti L; Vergelli C; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Quinn MT; Parisio C; Di Cesare Mannelli L; Ghelardini C; Giovannoni MP
Bioorg Chem; 2020 Jul; 100():103880. PubMed ID: 32388428
[TBL] [Abstract][Full Text] [Related]
4. Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.
Giovannoni MP; Schepetkin IA; Cilibrizzi A; Crocetti L; Khlebnikov AI; Dahlgren C; Graziano A; Dal Piaz V; Kirpotina LN; Zerbinati S; Vergelli C; Quinn MT
Eur J Med Chem; 2013 Jun; 64():512-28. PubMed ID: 23685570
[TBL] [Abstract][Full Text] [Related]
5. Gastrin-releasing peptide/neuromedin B receptor antagonists PD176252, PD168368, and related analogs are potent agonists of human formyl-peptide receptors.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Jutila MA; Quinn MT
Mol Pharmacol; 2011 Jan; 79(1):77-90. PubMed ID: 20943772
[TBL] [Abstract][Full Text] [Related]
6. 3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Leopoldo M; Lucente E; Lacivita E; De Giorgio P; Quinn MT
Biochem Pharmacol; 2013 Feb; 85(3):404-16. PubMed ID: 23219934
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists.
Vergelli C; Khlebnikov AI; Crocetti L; Guerrini G; Cantini N; Kirpotina LN; Schepetkin IA; Cilibrizzi A; Quinn MT; Rossi P; Paoli P; Giovannoni MP
Chem Biol Drug Des; 2021 Oct; 98(4):582-603. PubMed ID: 34148303
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel small-molecule agonists for human formyl peptide receptors and pharmacophore models of their recognition.
Kirpotina LN; Khlebnikov AI; Schepetkin IA; Ye RD; Rabiet MJ; Jutila MA; Quinn MT
Mol Pharmacol; 2010 Feb; 77(2):159-70. PubMed ID: 19903830
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of human formyl peptide receptor 1 (FPR1) by chromones and related isoflavones.
Schepetkin IA; Kirpotina LN; Khlebnikov AI; Cheng N; Ye RD; Quinn MT
Biochem Pharmacol; 2014 Dec; 92(4):627-41. PubMed ID: 25450672
[TBL] [Abstract][Full Text] [Related]
10. Structural changes of the ligand and of the receptor alters the receptor preference for neutrophil activating peptides starting with a formylmethionyl group.
Forsman H; Winther M; Gabl M; Skovbakke SL; Boulay F; Rabiet MJ; Dahlgren C
Biochim Biophys Acta; 2015 Jan; 1853(1):192-200. PubMed ID: 25447672
[TBL] [Abstract][Full Text] [Related]
11. Unleashing the power of formyl peptide receptor 2 in cardiovascular disease.
Prevete N; Poto R; Marone G; Varricchi G
Cytokine; 2023 Sep; 169():156298. PubMed ID: 37454543
[TBL] [Abstract][Full Text] [Related]
12. 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.
Cilibrizzi A; Quinn MT; Kirpotina LN; Schepetkin IA; Holderness J; Ye RD; Rabiet MJ; Biancalani C; Cesari N; Graziano A; Vergelli C; Pieretti S; Dal Piaz V; Giovannoni MP
J Med Chem; 2009 Aug; 52(16):5044-57. PubMed ID: 19639995
[TBL] [Abstract][Full Text] [Related]
13. Novel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2.
Lacivita E; Schepetkin IA; Stama ML; Kirpotina LN; Colabufo NA; Perrone R; Khlebnikov AI; Quinn MT; Leopoldo M
Bioorg Med Chem; 2015 Jul; 23(14):3913-24. PubMed ID: 25549897
[TBL] [Abstract][Full Text] [Related]
14. 4-Aroyl-3-hydroxy-5-phenyl-1H-pyrrol-2(5H)-ones as N-formyl peptide receptor 1 (FPR1) antagonists.
Kirpotina LN; Schepetkin IA; Khlebnikov AI; Ruban OI; Ge Y; Ye RD; Kominsky DJ; Quinn MT
Biochem Pharmacol; 2017 Oct; 142():120-132. PubMed ID: 28690139
[TBL] [Abstract][Full Text] [Related]
15. The formyl peptide receptor 1 exerts a tumor suppressor function in human gastric cancer by inhibiting angiogenesis.
Prevete N; Liotti F; Visciano C; Marone G; Melillo RM; de Paulis A
Oncogene; 2015 Jul; 34(29):3826-38. PubMed ID: 25263443
[TBL] [Abstract][Full Text] [Related]
16. Peptide length and folding state govern the capacity of staphylococcal β-type phenol-soluble modulins to activate human formyl-peptide receptors 1 or 2.
Kretschmer D; Rautenberg M; Linke D; Peschel A
J Leukoc Biol; 2015 Apr; 97(4):689-97. PubMed ID: 25724390
[TBL] [Abstract][Full Text] [Related]
17. Formyl peptide receptor 2 is an emerging modulator of inflammation in the liver.
Lee C; Han J; Jung Y
Exp Mol Med; 2023 Feb; 55(2):325-332. PubMed ID: 36750693
[TBL] [Abstract][Full Text] [Related]
18. Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.
Khlebnikov AI; Schepetkin IA; Quinn MT
Eur J Med Chem; 2010 Nov; 45(11):5406-19. PubMed ID: 20870313
[TBL] [Abstract][Full Text] [Related]
19. Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.
Schepetkin IA; Khlebnikov AI; Giovannoni MP; Kirpotina LN; Cilibrizzi A; Quinn MT
Curr Med Chem; 2014; 21(13):1478-504. PubMed ID: 24350845
[TBL] [Abstract][Full Text] [Related]
20. Stable formyl peptide receptor agonists that activate the neutrophil NADPH-oxidase identified through screening of a compound library.
Forsman H; Kalderén C; Nordin A; Nordling E; Jensen AJ; Dahlgren C
Biochem Pharmacol; 2011 Feb; 81(3):402-11. PubMed ID: 21095183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]